ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants

ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants

Summary: Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an indiv...

Full description

Bibliographic Details
Main Authors: Jeffrey Seow, Carl Graham, Sadie R. Hallett, Thomas Lechmere, Thomas J.A. Maguire, Isabella Huettner, Daniel Cox, Hataf Khan, Suzanne Pickering, Rebekah Roberts, Anele Waters, Christopher C. Ward, Christine Mant, Michael J. Pitcher, Jo Spencer, Julie Fox, Michael H. Malim, Katie J. Doores
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:Cell Reports
Subjects:
CP: Immunology
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124722005216

Internet

http://www.sciencedirect.com/science/article/pii/S2211124722005216

Similar Items